Epicore BioNetworks IncTSXV: EBN

Epicore BioNetworks Inc. Abandons IONA Acquisition

· Issued by Epicore BioNetworks Inc via CNW
CALGARY, Nov. 2 /CNW/ - Effective immediately, the Board of Directors of
Epicore BioNetworks Inc. announces that the Company will not pursue
acquisition of the shares of IONA Contractors Ltd. IONA is a Calgary, Alberta
Canada based firm that focuses on providing construction related services,
including environmental remediation, to the oil and gas, utility and other
industries. In an October 3, 2006 news release Epicore announced the signing
of a letter of intent with IONA. While the Company will not pursue IONA,
Epicore remains committed to building an environmental division based on
synergy with its extensive biotechnology expertise and its expanding
international business.

Epicore BioNetworks Inc. is a leading producer of environmental
biotechnology and animal nutrition products. It manufactures in the USA and
markets worldwide to a variety of industries to reduce environmental pollution
and increase operational productivity.
Epicore will hold its Annual General and Special Meetings of shareholders
at 10:00 am on Thursday, December 7, 2006 at the Calgary Petroleum Club,
319-5th Avenue SW, Calgary, Alberta, Canada.
Epicore BioNetworks Inc. is a public corporation with a registered office
in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange
(symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.)

This press release contains forward-looking statements that involve
significant risks and uncertainties. The actual results, performance or
achievements of the Company might differ materially from the results,
performance or achievements of the Company expressed or implied by such
forward-looking statements. Such forward-looking statements include, without
limitation, those regarding the development plans of the Company and the
expected timing and results of such development. We can provide no assurance
that such development will proceed as currently anticipated or that the
expected timing or results of such development will be realized. We are
subject to various risks, including the uncertainties of product development,
markets for our products and regulatory review, our need for additional
capital to fund our operations, our reliance on collaborative partners, our
history of losses, and other risks inherent in the biotechnology industry.


Epicore BioNetworks Inc on 6ix

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases